Burning Rock Biotech Ltd

We aim to transform precision oncology and early cancer detection. We are China's leading NGS-based cancer therapy selection company. Our cancer therapy selection platform uses advanced proprietary technologies, a comprehensive product portfolio, and a two-pronged commercial infrastructure. This infrastructure addresses larger hospitals through an in-hospital model and smaller hospitals through a central laboratory model. Our advanced technology platform integrates proprietary cancer therapy selection technologies using both tissue and liquid biopsies, including assay biochemistry, bioinformatics, and a patented laboratory information management system. Our proprietary HS library preparation technology works with poor quality and limited volume samples and enables enhanced sensitivity, which is critical for NGS-based cancer therapy selection, especially in China. Our in-depth cancer genomics insights, accumulated from a large number of tests performed since inception, enable us to process and accurately analyze genomic information. We achieve a turnaround time of approximately six days for regular oncology products, approximately twenty-five days for MRD products, and approximately nine days for early detection products. We offer a broad spectrum of NGS-based products. Our NGS-based cancer therapy selection test products assist physicians in selecting effective therapy for cancer patients. We primarily offer 33 NGS-based cancer therapy selection and prognosis prediction tests applicable to a broad range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer, using both tissue and liquid biopsy samples. Our core products, OncoCompass IO, OncoScreen IO, and OncoCompass Target, perform on par with global peers. We launched our MRD product, CanCatch, previously known as brPROPHET, in March 2022, which has demonstrated superior sensitivity and specificity to fixed panel in pre-operative ctDNA detection and post-operative MRD calling among relapsed patients.